Stockscreener 앱 받기
169.26
0.59%
0.99
Astrazeneca Plc 주식(AZN)의 최신 뉴스
AstraZeneca stock trades steady as recent earnings and oncology pipeline shape investor view - AD HOC NEWS
Why Did AstraZeneca (AZN) Stock Dip More Than the Market Today - Kavout | AI
AstraZeneca (AZN) Earnings Report Anticipated as Wall Street Clo - GuruFocus
AstraZeneca PLC (LSE:AZN) Q2 2026: Everything You Need To Know A - GuruFocus
AstraZeneca stock steadies as investors digest Q1 2026 growth and oncology momentum - AD HOC NEWS
AstraZeneca earnings up next after pipeline setback rattles investors By Investing.com - Investing.com South Africa
AstraZeneca moves closer to EU asthma approval for Trixeo Aerosphere - Yahoo Finance UK
AstraZeneca (AZN) Secures EU Approval Recommendation for Breast Cancer Treatment - GuruFocus
AstraZeneca stock trades steadily as oncology and rare disease growth supports earnings - AD HOC NEWS
AZN|AstraZeneca PLC|Price:168.290|Chg%:-1.440 - TradingKey
Analysis-AstraZeneca 'magic' faces rare test after trial failure, share slide - Yahoo Finance UK
AstraZeneca PLC expected to post earnings of $2.54 a shareEarnings Preview - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages AstraZeneca PLC (AZN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
AstraZeneca stock trades steadily as oncology and cardiovascular growth supports long term earnings - Ad-hoc-news.de
AstraZeneca Immune In Vax Trial Contract Suit, 10th Circ. Says - Law360
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AstraZeneca PLC (AZN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
EU Okays AstraZeneca’s Etcamah As US Wait Continues - insights.citeline.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN - PR Newswire
AstraZeneca's (AZN) Etcamah Secures EU Approval for Breast Cance - GuruFocus
AstraZeneca stock holds firm on oncology focus as recent results underline growth momentum - Ad-hoc-news.de
Why AstraZeneca (LSE:AZN) And GSK (LSE:GSK) Still Anchor UK Healthcare Stocks - Kalkine Media
Etcamah approval: AstraZeneca (NASDAQ: AZN) wins EU OK in HR+ breast cancer - Stock Titan
AstraZeneca's Etcamah combo approved for breast cancer treatment in EU - London South East
AstraZeneca PLC (AZN) Institutional Confidence - TradingKey
Astrazeneca Secures EU Approval For Etcamah In ER-positive Breast Cancer - DirectorsTalk Interviews
European Commission Approves Next-Generation SERD for First-Line Breast Cancer Treatment - Kalkine Media
REGAstraZeneca PLCEtcamah approved in the EU for ER+ breast cancer - TradingView
Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1st-line advanced ER-positive breast cancer - AstraZeneca
AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm - Business Wire
AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
AstraZeneca stock steadies as oncology and vaccines underpin earnings momentum - Ad-hoc-news.de
Jefferies says September lung data can offset AstraZeneca trial failure - Proactive financial news
London Deal Activity Keeps Healthcare Stocks In Focus As AstraZeneca (LSE:AZN) Sets The Tone - Kalkine Media
Stay Ahead of the Game With Astrazeneca (AZN) Q2 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance UK
Royalty Pharma acquires royalty stake in AstraZeneca drug By Investing.com - Investing.com Canada
Royalty Pharma acquires royalty stake in AstraZeneca drug - Investing.com
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune - The Manila Times
ASTRAZENECA : Jefferies gives a Buy rating - marketscreener.com
AstraZeneca stock trades steady as oncology and cardiovascular portfolio underpin growth - Ad-hoc-news.de
Earnings Preview: AstraZeneca to Report Financial Results on July 27 - 富途牛牛
AstraZeneca (AZN) Faces Changes Amid New U.S. Drug Tariff Regula - GuruFocus
AstraZeneca stock trades steady as oncology and vaccines underpin growth - Ad-hoc-news.de
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight - GlobeNewswire Inc.
AstraZeneca stock holds as earnings and pipeline milestones support valuation - Ad-hoc-news.de
AstraZeneca stock trades steady as oncology revenue supports 2025 outlook - Ad-hoc-news.de
ASTRAZENECA : JP Morgan gives a Buy rating - marketscreener.com
What Is Keeping AstraZeneca (LSE:AZN) At The Centre Of The Pharma Conversation? - Kalkine Media
AstraZeneca stock steadies as oncology growth supports guidance after latest quarterly update - Ad-hoc-news.de
Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating AstraZeneca PLC (AZN) And Encourages Stockholders to Connect - The National Law Review
AstraZeneca stock trades steadily as oncology and cardiovascular pipeline supports long term growth - Ad-hoc-news.de
Bronstein, Gewirtz & Grossman, LLC Is Investigating AstraZeneca PLC (AZN) And Encourages Investors to Connect - The National Law Review
AstraZeneca slips Monday, underperforms market - MarketWatch
AstraZeneca stock trades steadily as oncology and rare disease growth underpin earnings - Ad-hoc-news.de
What Is Putting AstraZeneca (LSE:AZN) At The Centre Of The Pharma Conversation? - Kalkine Media
AstraZeneca stock trades around recent highs as oncology growth supports valuation - Ad-hoc-news.de
AstraZeneca highlights rare diseases in $80bn revenue push - Financial Times
AstraZeneca PLC (AZN.L) Investor Outlook: Assessing a 25% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
AstraZeneca stock steady as recent earnings and pipeline progress frame investor debate - ad-hoc-news.de
AstraZeneca’s Fresh Cancer Drug Boost: What’s Behind the Latest Share Momentum? - Kalkine Media
AstraZeneca stock holds as investors await fresh evidence - ad-hoc-news.de
AstraZeneca | Pharmaceuticals, Vaccines, & Facts | Britannica Money - Encyclopedia Britannica
AstraZeneca stock steady as oncology and rare disease pipeline supports growth - ad-hoc-news.de
Why Is AstraZeneca (LSE:AZN) Drawing Fresh Attention On Oncology Approvals? - Kalkine Media
AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
AstraZeneca stock holds on to its earnings momentum - ad-hoc-news.de
AstraZeneca stock trades steady as oncology and rare disease pipeline underpins long term growth - ad-hoc-news.de
AstraZeneca stock trades steadily as oncology and rare disease pipeline underpins long term growth - ad-hoc-news.de
AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossma - The National Law Review
AstraZeneca stock holds as 2025 revenue and profit stay in focus - Ad Hoc News
0.72%
1.22%
자본화:
|
볼륨(24시간):